Journal
ADVANCED DRUG DELIVERY REVIEWS
Volume 55, Issue 2, Pages 217-250Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/S0169-409X(02)00180-1
Keywords
poly (ethylene glycol); prodrugs; tripartate prodrugs; camptothecin; paclitaxel; daunorubicin; ara-C; amphotericin B; 6-mercaptopurine; doxorubicin; lysozyme
Categories
Ask authors/readers for more resources
The current review presents an update of drug delivery using poly(ethylene glycol) (PEG), that focuses on recent developments in both protein and organic drugs. Certainly the past 10 years has resulted in a renaissance of the field of PEG drug conjugates, initiated by the use of higher molecular weight PEGs (M-w > 20,000), especially 40,000 which is estimated to have a plasma circulating t(1/2) of approximately 10 h in mice. This recent resuscitation of small organic molecule delivery by high molecular weight PEG conjugates was founded on meaningful in vivo testing using established tumor models, and has led to a clinical candidate, PEG-camptothecin (PROTHECAN(R)), an ester based prodrug currently in phase 11 trials. Additional applications of high molecular weight PEG prodrug strategies to amino containing drugs are presented: similar tripartate systems based on lower M-w PEG and their use with proteins is expounded on. The modification of a benzyl elimination tripartate prodrug specific for mercaptans is presented, and its successful application to 6-mercaptopurine giving a water soluble formulation is discussed. Recent novel PEG oligonucleotides and immumoconjugates are also covered. Clinical results of FDA approved PEGylated proteins are also presented. (C) 2002 Elsevier Science B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available